Facilitating Drug Discovery With Induced Pluripotent Stem Cells – News-Medical.net

Download Axols free white paper - "Induced Pluripotent Stem Cells: recapitulating disease to facilitate drug discovery" Understand more about how iPSC-derived cells can improve any drug development research program by supplying a physiologically relevant model, which is capable of representing a disease population. This enables research in multiple stages of the development pipeline. This white paper comprises cases wherein iPSC-derived cells have been utilized for target identification, target validation, lead optimization and safety testing, as a means of reducing failure rates of drug candidates.

Read more
Europe midday: Stocks track gains on Wall Street, drug and biotech shares higher – ShareCast

Stocks in the rest of Europe were putting in a small bounce on Tuesday, with investors taking their cue from US markets, which had finished higher the day before on the hope that the worst scenarios in the Middle East could yet be averted. That was despite the head of Iran's national security council, Ali Shamkhani's, reported threat of a "historic nightmare" for the US. "Even though tensions between the US and Iran remain high, sentiment in equity markets has turned positive, as European indices are showing modest gains this morning

Read more
ThermoGenesis Holdings Announces That ImmuneCyte Joint Venture Receives $3.0 Million Equity Investment – P&T Community

RANCHO CORDOVA, Calif., Jan. 3, 2020 /PRNewswire/ --ThermoGenesis Holdings, Inc.(Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that ImmuneCyte Life Sciences, Inc. ("ImmuneCyte"), an 80/20 joint venture between HealthBanks Biotech (USA) and ThermoGenesis, has closed a $3.0 million equity investment with a private institution

Read more